LMLyndsey S. Mixson

Lyndsey S. Mixson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lyndsey S. Mixson has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Community-based health navigation to reduce drug-related harms in rural settings: A pooled analysis of two intervention trials

    by Ryan P. Westergaard, L. Sarah Mixson, Hailey K. Ballard, April M. Young, Robin M. Nance, Joseph A. Delaney, Mikaela Becker, Rachel E. Gicquelais, Hannah L.F. Cooper

  • Characterizing Rural Substance Use Treatment Experiences Among Individuals Under Community Correctional Supervision

    by Tawandra L. Rowell-Cunsolo, Courtney Blanford, David Seal, Wiley D. Jenkins, L. Sarah Mixson, Daniel B. Hoover, Thomas J. Stopka, Carrie B. Oser, Peter D. Friedmann, Gordon S. Smith, et al.

    Objectives: More than 3.7 million individuals are currently under community correctional supervision (eg, probation, parole) in the United States, and approximately 46% of them use illicit substances. Although high rates of substance use and the need for high-quality treatment for this population have been acknowledged, additional research is needed to characterize treatment needs among this population, especially those residing in rural or underserved communities. Methods: Data were drawn from the Rural Opioid Initiative, a study focused on substance use in rural communities across 10 states in the United States. Our analyses examined past 6-month substance use disorder (SUD) treatment receipt among 978 participants under community supervision in the past 6 months. Results: More than 55 percent had engaged in some type of treatment for substance use in the past 6 months; among those, nearly half (46%) had enrolled in inpatient or residential treatment. The odds of receiving treatment were greater among women than men (odds ratio [OR] 1.49, 95% confidence interval [CI] [1.15–1.94]), those with health insurance coverage (OR 3.10, 95% CI: [2.24–4.31]) and those with access to transportation (OR 1.54, 95% CI: [1.08–2.20]). Treatment receipt was lower among participants who used methamphetamine/amphetamine as their primary drug of choice compared with other substances. Conclusions: Initiatives to increase SUD treatment engagement among rural people who use drugs under community correctional supervision should address gaps in insurance coverage, transportation access, and treatment modalities that target stimulant use disorders. Gender-specific needs should also be considered when creating substance use interventions for this population.

  • Open Access

    Injection Drug Use and Sexual Behaviors Associated With Infection Transmission and Access to Harm Reduction for People Who Use Drugs and Sell Sex in the Rural US

    by L. Sarah Mixson, April M. Young, Judith I. Tsui, Wiley D. Jenkins, Mai T. Pho, David W. Seal, Lydia N. Drumright, Stephanie A. Ruderman, Thomas J. Stopka, P. Todd Korthuis, et al.

    Despite the recognition of substance use and sex work as public health issues, the intersection of these areas, especially within the rural US, is an area of special importance. The Rural Opioid Initiative comprises of eight research cohorts spanning 10 states and 65 rural US counties. Between 1/2018-3/2020, individuals who reported past 30-day substance injection or opioid misuse were recruited. Analyses were restricted to people who use drugs (PWUD) who reported trading “vaginal or anal sex for drugs, money, housing, or other things you need” in the past 30 days. We analyzed cross-sectional associations between injection drug use and sexual behaviors associated with hepatitis C virus (HCV)/HIV infection transmission, access to harm reduction, and HCV status among PWUD and engaged in sex work in rural US areas. Of the 2045 participants, 9% (n=180) reported engagement with sex work, with just over half being women (58% [n=104]). In adjusted models, people who engaged in sex work, compared to PWUD who did not, had higher prevalence ratios of past 30-day receptive syringe sharing (adjusted prevalence ratio [aPR]=1.69, 95% Confidence Interval [95%CI]=1.44–1.98), practice of multiple injections per injection episode (aPR = 1.28, 95% CI = 1.15–1.43), practice of syringe mediated drug sharing (aPR=1.50, 95% CI=1.32–1.71), condomless sex (aPR=1.62, 95% CI=1.48–1.77) and condomless sex with someone who injects drugs (aPR=2.05, 95% CI=1.76–2.39). PWUD engaged in sex work were less likely to report easy condom access (aPR=0.88, 95% CI=0.80–0.96), while no significant differences were observed for most other harm reduction access measures. PWUD engaged in sex work in the rural US had higher likelihood of injection drug use and sexual behaviors associated with HCV/HIV infection transmission, while having lower use of and access to condoms. This study emphasizes the importance of ensuring affordable access to condoms within the context of harm reduction services, especially given the limited access to health care and supportive services, particularly in rural communities.

  • Open Access

    Correlates of Rural Naloxone Possession Among People Who Use Drugs: A Multi‐State Cross‐Sectional Analysis

    by P. Quincy Moore, L. Sarah Mixson, Rebecca Bolinski, David C. Colston, Hannah L. F. Cooper, Heidi M. Crane, Jackson Devadas, Judith Feinberg, Peter D. Friedmann, Rachel E. Gicquelais, et al.

    Purpose: Naloxone administration by laypersons is proven to reduce opioid overdose mortality. Despite legislative advances, people who use drugs (PWUD) in rural settings face unique barriers to naloxone possession. This study aims to examine naloxone possession and identify its correlates among a large, geographically diverse sample of people who either use opioids or inject drugs in rural areas. Methods: We performed a cross‐sectional analysis using Rural Opioid Initiative (ROI) data from rural counties of ten US states. Study sites administered a harmonized survey instrument of 3048 PWUD recruited from January 2018 to March 2020. The primary outcome was current naloxone possession. Potential correlates were identified through review of the literature. Data were collected on demographics, drug use behaviors, overdose experiences, access to care, and addiction treatment. Data were analyzed using descriptive statistics, bivariate associations, and multivariable prevalence ratios. Findings: Among 3008 participants included in the analysis, 36.4% reported possessing naloxone. Naloxone possession was associated with younger age, illegal income sources, past 30‐day opioid use, personal history of overdose, witnessing an overdose, knowing someone who died from an overdose, current injection drug use, and receiving syringes from syringe service programs (SSPs). No association was found between access to care and naloxone possession. Conclusions: Only 36% of high‐risk rural PWUD possessed naloxone. Factors such as injection drug use, overdose history, and SSP access increased the likelihood of naloxone possession. These findings highlight the need for targeted naloxone distribution strategies in rural areas, considering the unique barriers faced by rural PWUD.

  • Open Access

    Community Resilience Estimates and HIV Health Outcomes: Insights from the CNICS Cohort

    by L. Sarah Mixson, Stephanie A. Ruderman, Sonia Napravnik, Lindsay E. Browne, Deana M. Agil, Heather I. Henderson, Bridget M. Whitney, Mari M. Kitahata, Geetanjali Chander, Joseph A. C. Delaney, et al.

    This study aims to better understand the association between community social vulnerabilities (e.g., income-to-poverty ratio, health insurance coverage) and the ability of people with HIV (PWH) to achieve viral suppression and optimal CD4 cell count levels. We conducted an observational study within the CFAR Network of Integrated Clinical Systems (CNICS) cohort of adult PWH in care at two CNICS sites between 1/2015 and 3/2023 with an identifiable residential address and HIV-related laboratory measures. Our exposure of interest, 2022 Community Resilience Estimates (CRE) from the US Census Bureau, is calculated at the census tract level and categorized as 0, 1–2, or 3–10 social vulnerabilities that impact community resilience. Outcomes included individual-level unsuppressed HIV viral load (≥ 50 copies/mL) and low CD4 count (< 350 cells/mm 3 ). We estimated prevalence ratios and 95% confidence intervals (CI) using multivariable relative risk regression clustered by census tract, adjusting for individual-level demographic characteristics, site, and year of outcome measurement. Among 3,191 PWH, 342 (11%) were virally unsuppressed and 528 (17%) had low CD4 cell count. Compared to PWH in tracts with 0 vulnerabilities, those living in census tracts with 1–2 social vulnerabilities were 1.28 times more likely (95%CI: 1.00-1.63) to be virally unsuppressed. Those in census tracts with ≥ 3 social vulnerabilities were 1.95 times more likely (95%CI: 1.22–3.10) to be virally unsuppressed and were 1.51 times more likely (95%CI: 1.12–2.04) to have low CD4 cell counts. In the context of PWH, the CRE could be used to highlight areas for targeted interventions based on community-level influences to improve HIV-related outcomes.

  • Prevalence and correlates of multiple injections per injection episode among people who inject drugs in rural U.S. communities

    by L. Sarah Mixson, William Zule, Stephanie A. Ruderman, Judith Feinberg, Thomas J. Stopka, Adams L. Sibley, Suzan M. Walters, Georgiy Bobashev, Ryan Cook, Karli R. Hochstatter, et al.


  • Benzodiazepines and Opioid co-use Among Rural People Who Use Drugs: Findings From the Rural Opioid Initiative

    by L. Sarah Mixson, Arvind Venkataraman, Lydia N. Drumright, Bridget M Whitney, Wiley D. Jenkins, Peter D. Friedmann, William A. Zule, Jennifer Havens, Stephanie A Ruderman, Thomas J. Stopka, et al.

    Background: Benzodiazepines and opioids are among the most frequently misused psychoactive substances, but their patterns of co-use (polysubstance use) in rural areas are unclear. As resources to address substance use are disproportionally scarce in rural areas, a better understanding of this polysubstance use is critical to allocate and direct interventions. Methods: The Rural Opioid Initiative comprises 8 research cohorts spanning 10 states and 65 rural counties. Participants were recruited from January 2018 to March 2020 and eligibility included past 30-day opioid use by any route or past 30-day injection of any substance. Analyses were restricted to participants reporting past 30-day opioid use and either benzodiazepine or stimulant use. We described bivariate cross-sectional associations between benzodiazepine+opioid use, compared with stimulant+opioid use, and substance use behaviors, health outcomes, injection drug use, addiction treatment, and criminal legal system involvement. Results: Of the 1107 ROI participants that met inclusion criteria, 10% (n = 107) reported benzodiazepine+opioid use, and 90% (n = 1000) reported stimulant+opioid use. The benzodiazepine+opioid group, compared with the stimulant+opioid group, had a higher use of opioid pain medication (73% vs 55%), gabapentin (43% vs 23%), and clonidine (12% vs 4%) to get high and used these substances more frequently; they also reported more frequent heavy episodic drinking (6.1 days per 30 days, SD = 9.4 vs 4.1 days, SD 7.5). The benzodiazepine+opioid group reported a lower prevalence in the past 6 months of law enforcement stop-and-search incidents (29% vs 48%), arrests (11% vs 28%), probation (22% vs 34%), jail/prison (18% vs 41%), and fewer days in jail/prison (4.7, SD = 19.1 days vs 15.9, SD = 35.7 days). Conclusion: We found that benzodiazepines+opioids use was associated with more heavy episodic drinking and gabapentin use, and lower prevalence of criminal legal system involvement. These data suggest that individuals reporting benzodiazepines+opioids use have distinct behavioral patterns and outcomes that require targeted interventions for rural populations.


  • Open Access

    Serious Bacterial Infections and Hepatitis C Virus Among People Who Inject Drugs: A Syndemic or Intertwined Epidemics?

    by Thomas J. Stopka, Robin M. Nance, L. Sarah Mixson, Hunter Spencer, Judith I. Tsui, Judith M. Leahy, Mai T. Pho, Jean DeJace, Judith Feinberg, April M. Young, et al.

    Limited research has examined the possible synergistic interrelationships between serious bacterial infections (SBIs) of the heart (i.e., endocarditis), bone, spine, brain, or joints (e.g., osteomylelitis) and hepatitis C virus (HCV) infections. We examined whether syndemic interactions existed between SBI, HCV, and substance-use-related factors in rural communities, hypothesizing that injection-mediated risks elevated the likelihood for both SBIs and HCV infections, which could be exacerbated by synergistic biological–biological or biological and social interactions. We calculated the prevalence ratios (PRs) of past-year SBI associated with each risk factor in separate models. Effect modification among significant risk factors was assessed using multiplicative interaction. Among 1936 participants, 57% were male and 85% White, with a mean age of 36 years. Eighty-nine participants (5%) reported hospitalization for an SBI in the year prior to the survey. More than half tested HCV-antibody-positive (58%); 62 (5.6%) of the participants with a positive HCV antibody result reported past-year hospitalization with an SBI. Injection behaviors were correlated with other SBI risk factors, including multiple injections in the same injection event (MIPIE), injection equipment sharing, and fentanyl use. In adjusted models, MIPIE (PR: 1.79; 95% confidence interval [CI]: 1.03, 3.11) and fentanyl use (PR: 1.68; 95% CI: 1.04, 2.73) were significantly associated with past-year SBI. Our analyses pointed to co-occurring epidemics of SBI and HCV, related to the cumulative health effects of fentanyl use contributing to frequent injections and MIPIE. Both the SBI and HCV epidemics present public health challenges and merit tailored interventions.


  • Top Cited Papers

    Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study

    by T.J. Stopka, A.T. Estadt, G. Leichtling, J.C. Schleicher, L.S. Mixson, J. Bresett, E. Romo, P. Dowd, S.M. Walters, A.M. Young, et al.


  • Open Access

    Behavioral and Health Outcome Differences by Heroin or Methamphetamine Preference Among People in Rural US Communities Who Use Both Substances

    by L Sarah Mixson, Bridget M Whitney, Wiley D Jenkins, Thomas J Stopka, P Todd Korthuis, Lydia N Drumright, Stephanie A Ruderman, Peter D Friedmann, Mai T Pho, April M Young, et al.

    Background: The United States’ (US) opioid overdose epidemic has evolved into a combined stimulant/opioid epidemic, a pattern driven in part by mitigating opioid overdose risk, variable substance availability, and personal preferences. This study aimed to investigate the association between self-reported substance preference (heroin or methamphetamine) and behavioral/health outcomes among individuals who used both heroin and methamphetamine in the rural US. Methods: The Rural Opioid Initiative is a consortium of 8 research cohorts from 10 states and 65 rural counties that recruited individuals reporting past 30-day injection of any substance or opioid substance use by any route from 1/2018 to 3/2020. Analyses were restricted to participants ⩾18 years, who self-reported either heroin or methamphetamine as their preferred substance and past 30-day use of both heroin and methamphetamine. We examined cross-sectional associations between preferred substance (heroin versus methamphetamine) and behavioral and health outcomes using random effects meta-analysis with adjusted regression models. Results: Among 1239 participants, 61% (n = 752) reported heroin as their preferred substance. Adjusting for age, sex, and race/ethnicity, methamphetamine preference was associated with lower prevalence ratios for current naloxone possession (adjusted prevalence ratio [aPR] = 0.68; 95% Confidence Interval [95% CI] = 0.59-0.78; P-value ⩽ .001), of ever being told they had the hepatitis C virus (HCV; aPR = 0.72; 95% CI: 0.61-0.85; P-value ⩽ .001) and a personal history of overdose (aPR = 0.81; 95% CI = 0.73-0.90; P-value ⩽ .001). Conclusion: In our study analyzing associations between preferred substance and various behavioral and health outcomes amongst people who use both heroin and methamphetamine, a majority of participants preferred heroin. Methamphetamine preference was associated with lower prevalence of naloxone possession, ever being told they had HCV, and prior history of an overdose. This study underscores the need for targeted harm reduction services for people who prefer methamphetamine in rural areas.